Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Centocor ( CNTO ) -- Ignore unavailable to you. Want to Upgrade?

To: edna lipiner who wrote (618)	4/2/1998 11:18:00 PM
From: Robohogs	Read Replies (1) \| Respond to of 965

Sorry for my seeming earlier panic - this stock's sudden 4-10 point moves finally overwhelmed me. I did keep 1000 shares (1/2 position) based on various posts and based on Merrill reiteration of Focus One list. Merrill analyst commented that he was surprised by unstable angina indication but that he was not changing his estimates for Centocor eps or Reopro sales. He maintained 1-1 status and indicated that April could be a difficult month but that now was a time to buy. General consensus seems to be that there are two camps (i.e., there is no general consensus). One camp is having orgasms over CORR (they talk Reopro down and ooze about Corr's greatness - includes To at DMG and this doctor at AmeriCal (sp?)). The other camp discusses the data and how CNTO will have to be the standard of choice to avoid lawsuits. While CORR indication is 4x as large as Reopro, I have to believe that CNTO will get some off-label use (maybe a lot therefore ramping sales earlier than expected) while CORR will get $0, yes $0 (or close) of angioplasty sales. How could any doctor in good conscious use CORR given CNTO's test data in this area. I am still worried about the Avakine situation, although early review must mean something to hope for. Let's hope for a partner soon. By the way, I finally did join full time (so I could post this message). Here's to many future profits and 10K on the Dow by late summer (the bubble gets bigger).

To: edna lipiner who wrote (618)	4/3/1998 2:01:00 AM
From: FNS	Respond to of 965

edna: <<Stay on the roller coaster to 70.>> Sounds mighty good to me!!! I'm with you. Incidentally, CORR got banged on 1/29 (partial publication): <<<Samad said the panel took issue with COR's data showing that in its so-called PURSUIT study of almost 11,000 patients with unstable angina, Integrilin reduced the rate of death or serious heart attack from 15.7 percent to 14.2 percent. "The panel felt the way COR did its statistical analysis was not done properly," he said, and thus failed to show statistically significant efficacy for the angina patients. And although the panel did recommend the drug for patients undergoing angioplasty procedures, Samad said it cited serious concern about bleeding at the dose preferred by COR. "There was heated debate about the dosing issue," he said, with COR arguing that the lower dose suggested by the FDA panel had sub-optimal therapeutic benefits. The FDA almost always follows the recommendations of its advisory panels. If the FDA follows the panel's recommendation and approves Integrilin for angioplasty, a procedure in which surgeons insert a small balloon to stretch out blocked arteries, it would compete head-on with Centocor Inc (NASDAQ:CNTO) anti-platelet drug ReoPro. ReoPro, marketed by Eli Lilly and Co (NYSE:LLY) for both angioplasty and unstable angina, had revenues in 1997 of about $250 million, Samad said, mostly from angioplasty patients.>> -------------------------------------------------------------- I believe a previous post indicated that Reopro was not approved for unstable angina! Am I missing something??? My understanding is the CNTO got expanded use of Reoproas, as indicated above. (Someone help!) Incidentally, the the daily closing 3-month chart still maintains CNTO in uptrend. While the next few weeks may be shaky, there is support at 42 and 40...shakeout can be expected, so hold on, that is you believe Reopro is the drug of choice (IMHO). Good luck, FNS